BIOT Tapped to Advance CelSiege's IN01 Cancer Immunotherapy in Asia

INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) has been appointed by CelSiege Biosciences Inc. as its authorized introduction and business development representative in Japan and the People’s Republic of China for IN01, a clinical-stage cancer immunotherapy program. The non-exclusive appointment, formalized through a Letter of Authorisation signed on September 18, 2026, by CelSiege Founder and Director Johan Indot, allows BIOT to introduce the IN01 Program to prospective strategic partners, investors, pharmaceutical and biotechnology companies, medical institutions, research organizations, and investment funds in both countries. BIOT may also facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing, and commercialization, though any definitive transaction remains subject to separate negotiations, due diligence, and definitive agreements.

IN01 is an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor (EGF). It is designed to stimulate the patient’s immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer cells. The lead indication is squamous non-small cell lung cancer (sqNSCLC), with potential expansion into colorectal, head-and-neck, and other cancers. According to the International Agency for Research on Cancer, lung cancer was the world’s most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases and 1.8 million deaths. Non-small cell lung cancer accounts for about 80% to 85% of lung cancer cases, and Fortune Business Insights estimates the global NSCLC therapeutics market at approximately $38.49 billion in 2025.

Tomoki Nagano, Chief Executive Officer of BIOT, expressed confidence in IN01, stating, “We believe IN01 is a promising clinical-stage program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the patients who need it.” He highlighted that Japan and China have the world’s largest lung cancer patient populations and world-class clinical research capabilities, placing them at the center of unmet medical needs in oncology. “As CelSiege’s authorized representative in these two markets, BIOT will work with a strong sense of ownership to identify partners and pursue collaborations that can advance the development and commercialization of IN01. Our enduring aspiration is to bring more smiles to patients and their families.”

CelSiege Biosciences is a biotechnology company headquartered in Marseille, France, with operations in the United States, focused on the research and development of active immunotherapies. Its proprietary B-cell-mediated platform is designed to stimulate polyclonal antibody responses against disease-associated ligands. For more information, visit CelSiege Biosciences. BIOT is a diversified healthcare and biotechnology company focused on developing and expanding businesses across beauty, wellness, regenerative medicine, and related healthcare sectors. For more information, please visit https://instinct-biot.com/.